/
We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of Pfizer Inc. 2025 Form 10-K 3 biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most …
$25.63
$0.55 (-2.10%)
Price from 2 days ago
35.60% operating margin is above average. ROIC at 11.42%.
Revenue declined 1.6% YoY. The question is whether this is cyclical or a structural shift.
Net debt of $56.93B represents 6.3x FCF, leverage limits flexibility.
19.6x earnings, 15.5x FCF. Valuation is in a reasonable range. The main question is whether the business can re-accelerate or if current trajectory is already priced in.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$63.31B
▼ -1.6% YoY
Net Income (TTM)
$7.49B
▼ -3.2% YoY
Op. Margin
34.90%
▲ +3.8pp YoY
ROIC
14.16%
▲ +1.4pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
$9.48B
▼ -7.7% YoY
Op. Cash Flow (TTM)
$11.98B
▼ -8.2% YoY
Net Debt
$54.53B
Cash & Equiv.
$9.89B
5Y CAGR: +8.5%
5Y CAGR: -5.7%
Continue Research